Linked Life Data

21568365

Source:http://linkedlifedata.com/resource/pubmed/id/21568365

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-5-16
pubmed:abstractText
Rituximab is a recombinant chimeric murine/human monoclonal IgG(1-?) antibody. It binds specifically to the CD20 antigen on normal and malignant B lymphocytes and produces complement-dependent and antibody-dependent cytotoxicity and induces apoptosis in these cells. Prolonged treatment with rituximab in patients with follicular lymphoma results in a sustained reduction in circulating B lymphocytes. Two years of single-agent maintenance therapy with rituximab significantly prolonged progression-free survival (primary endpoint) compared with observation in patients with follicular lymphoma who were responsive to first-line induction therapy with rituximab plus chemotherapy. Furthermore, maintenance therapy with rituximab significantly delayed the time to the next antilymphoma treatment and the next chemotherapy compared with observation in these patients. Rituximab had an acceptable tolerability profile as single-agent maintenance therapy in patients with follicular lymphoma with no new or unexpected adverse events compared with induction therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0012-6667
pubmed:author
pubmed:copyrightInfo
© 2011 Adis Data Information BV. All rights reserved.
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
71
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
885-95
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.
pubmed:affiliation
Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
pubmed:publicationType
Journal Article, Review